“Biomarkers” cover a wide array of measurable indicators—from lab tests to imaging and genomic data—used to predict clinical outcomes like mortality, treatment response, relapse, or complications. Their relevance is disease‑specific, but a few families of biomarkers are now deeply embedded in guideline‑driven care and have strong evidence bases for prognostication in major conditions (cardiovascular disease, oncology, sepsis, neurodegeneration, and chronic inflammatory disorders).

Major biomarker classes with strong predictive value

1. Cardiovascular disease

• Cardiac troponins (high‑sensitivity troponin I/T)

• Central to acute coronary syndrome (ACS) diagnosis and risk stratification.

• Elevated and dynamic changes predict short‑ and long‑term mortality and reinfarction risk.

• BNP / NT‑proBNP

• Reflects ventricular wall stress; high levels predict worse outcomes in heart failure, including hospitalization and death.

• Also useful in risk‑stratifying patients with dyspnea or suspected HF.

Why they matter: Heart disease is a leading cause of morbidity/mortality, and these biomarkers are widely available, standardized, and deeply embedded in guidelines, making them among the most clinically impactful prognostic tools.

2. Oncology

• PD‑L1 expression

• In non‑small cell lung cancer and several other malignancies, high PD‑L1 expression on tumor or immune cells predicts better response to checkpoint inhibitors (e.g., anti‑PD‑1/PD‑L1 therapies) and thus improved progression‑free and overall survival.

• Tumor mutational burden (TMB) and MSI status

• High TMB and microsatellite instability‑high (MSI‑H) tumors tend to respond better to immunotherapy and have distinct prognoses.

• Circulating tumor DNA (ctDNA)

• Emerging as a powerful biomarker for minimal residual disease, relapse prediction, and treatment response in multiple cancers.

Why they matter: They directly inform treatment selection and intensity, significantly altering prognosis and resource use in high‑burden diseases.

3. Sepsis and severe infection

• Procalcitonin (PCT)

• Elevated PCT correlates with bacterial infection severity and prognosis in sepsis; trends over time can help predict mortality and guide antibiotic de‑escalation.

• Lactate

• High serum lactate, particularly if persistent after resuscitation, is a robust predictor of mortality in septic shock and other critical illnesses.

Why they matter: Sepsis is a leading cause of ICU admissions and death; PCT and lactate are widely used for early risk stratification and therapy guidance.

4. Systemic inflammation and chronic disease

• C‑reactive protein (CRP) and high‑sensitivity CRP (hs‑CRP)

• Elevated CRP is a non‑specific but useful predictor of worse outcomes in a range of conditions, from cardiovascular disease to autoimmune disorders and infections.

• hs‑CRP adds prognostic information in cardiovascular risk assessment beyond traditional risk factors.

Why they matter: They provide a broad, low‑cost signal of inflammatory burden that helps risk‑stratify large patient populations.

5. Neurology and neurodegeneration

• Amyloid‑β and tau (CSF and plasma biomarkers)

• Combinations of amyloid and tau markers now predict Alzheimer’s disease risk and progression, and are moving into earlier‑stage diagnosis and trial enrichment.

• Neurofilament light chain (NfL)

• Emerging as a marker of axonal injury and disease activity in multiple sclerosis and other neurodegenerative diseases, with prognostic value for disability progression.

Why they matter: As disease‑modifying therapies expand, these biomarkers guide who to treat, how aggressively, and when to escalate.

Cross‑cutting themes

• No single “best” biomarker: Predictive value is inherently context‑dependent. A troponin value is highly informative in suspected myocardial infarction, but not in cancer prognosis; PD‑L1 is critical in immuno‑oncology, irrelevant in sepsis.

• Panels and composite scores: Combining biomarkers (e.g., troponin + BNP + CRP) with clinical variables often yields better prognostic performance than any single marker.

• Accessibility vs. sophistication: Many of the most impactful biomarkers (troponin, BNP, CRP, lactate, PCT) are simple lab tests available even in non‑tertiary settings, which amplifies their real‑world value.

Counterarguments and limitations

• Over‑reliance: Biomarkers can be over‑interpreted without sufficient clinical context, leading to overtreatment or misclassification.

• Cost and availability: More advanced biomarkers (ctDNA, detailed genomic panels, advanced neuroimaging markers) are expensive and not widely accessible, limiting their population‑level impact today.

• Population differences: Cutoffs and predictive power may vary by age, sex, comorbidities, and ethnicity; local validation is critical.

Practical implications for clinicians and researchers

• In cardiology, troponin and BNP/NT‑proBNP remain cornerstone prognostic tools; incorporating them into risk scores (e.g., GRACE, HEART, HF scores) improves decision‑making.

• In oncology, PD‑L1, MSI/TMB, and increasingly ctDNA are central to choosing immunotherapy and monitoring response.

• In critical care, lactate and PCT (plus clinical severity scores) guide sepsis resuscitation, ICU triage, and antibiotic stewardship.

• In chronic inflammatory and neurodegenerative diseases, CRP, autoimmune serologies, and neuro‑biomarkers like tau and NfL are reshaping early diagnosis and treatment‑intensity decisions.